Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Scancell Logo
Scancell Growth Score
61
CB Rank
59786
Heat Score
73
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Founded
obfuscation
PublicPost-IPO Equity Nottingham, Nottingham, United Kingdom11-50 www.scancell.co.uk
Biotechnology
Health Care
Overview

Scancell
Total Funding
obfuscation
Growth Score
61
Heat Score
73

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score61
-17 pts
in past quarter
Heat Score 73
19 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Scancell

CB Rank
59786
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Founded
obfuscation
PublicPost-IPO Equity Nottingham, Nottingham, United Kingdom11-50 www.scancell.co.uk
Biotechnology
Health Care

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Scancell Ltd.
Operating Status Active
Stock Symbol  LSE:SCLP
Company Type For Profit
Founders  Lindy Durrant
About the Company

Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1

produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Phone Number +44 20 7245 1100
Contact Email scancell@fticonsulting.com
Predictions & Insights

Growth Insight

See this Growth Insight
Scancell is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

ImmunoBody
A platform for developing cancer vaccines that induce immune responses by targeting specific epitopes on cancer cells.
Moditope
A platform for creating cancer vaccines that stimulate the immune system by targeting post-translational modifications of proteins.

Research & Development

Scancell is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
4
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Panmure Liberum Logo
Panmure Liberum
—
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
—
Panmure Liberum Logo
Panmure Liberum
—
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
—
Panmure Liberum Logo
Panmure Liberum
—
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
—
Panmure Liberum Logo
Panmure Liberum
—
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
—
Panmure Liberum Logo
Panmure Liberum
—
Post-IPO Equity - Scancell Logo
Post-IPO Equity - Scancell
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 5 Contacts 34

Employee Profiles

News

News and Press

News•Jun 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 28, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

981
113.73%
 in past month

IT Spend

$441.9KThis year, Scancell is projected to spend $441.9K on IT, according to Aberdeen.

Actively Used Products

20Scancell uses 20 technology products and services including HTML5, .NET 4.5, and  Google Analytics, according to G2 Stack.

Active Website Tech Count

8Scancell is actively using 8 technologies for its website, according to BuiltWith. These include DNSSEC, jsDelivr, and  CommonCrawl Top 10m.

Total IP

37The intellectual property of Scancell includes 27 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Scancell has registered 10 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Scancell's headquarters? Scancell is located in Nottingham, Nottingham, United Kingdom.Who invested in Scancell? Scancell has 9 investors including Panmure Liberum and  Vulpes Investment Management Pte Ltd.When was the last funding round for Scancell? Scancell closed its last funding round on
obfuscation
from a Post-IPO Equity round.How much funding has Scancell raised to date? Scancell has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(d80a5b2 1)
|